All In Biotech

Drug Trial Radar · NCT00764374

A Long-term, Open-label, Uncontrolled Trial of YM443 (Z-338) in Patients With Functional Dyspepsia

Last checked: Nov 19, 2026Latest source record: Oct 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Aug 2008

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Oct 2, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To examine the safety and efficacy of Z-338 (YM443) after long-term administration in patients with functional dyspepsia, and also to examine the pattern of long-term administration.

Conditions

  • Dyspepsia
  • Functional Dyspepsia

Interventions

  • YM443Drug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject's global assessmentTime frame: Every week

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hokkaido, Japan

  • Site not named

    Kansai, Japan

  • Site not named

    Kantou, Japan

  • Site not named

    Kyushu, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.